Treatment of infections caused by metallo-beta-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region.
This study reviewed 56 patients with significant metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa infections between May 2002 and March 2004 to identify features associated with mortality. Immunosuppression (p 0.002), bacteraemia (p 0.08) and inadequate antimicrobial therapy (p <0.001) were associated with death. Among those patients treated with adequate therapy, the use of multiple drug treatment regimens (two or three active agents) was associated with a non-significant two-fold increase in survival (p 0.45). Further prospective studies are warranted to determine the optimal treatment of MBL-producing P. aeruginosa infections.
Parkins
M D
MD
Department of Medicine, Calgary, Alberta, Canada.
Pitout
J D D
JDD
Department of Pathology and Laboratory Medicine, Calgary, Alberta, Canada; Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada; Division of Microbiology, Calgary Laboratory Services, Calgary, Alberta, Canada.
Church
D L
DL
Department of Medicine, Calgary, Alberta, Canada; Department of Pathology and Laboratory Medicine, Calgary, Alberta, Canada; Division of Microbiology, Calgary Laboratory Services, Calgary, Alberta, Canada.
Conly
J M
JM
Department of Medicine, Calgary, Alberta, Canada; Department of Pathology and Laboratory Medicine, Calgary, Alberta, Canada; Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada; Centre for Anti-microbial Resistance, University of Calgary, Calgary Health Region and Calgary Laboratory Services, Calgary, Alberta, Canada.
Laupland
K B
KB
Department of Medicine, Calgary, Alberta, Canada; Department of Pathology and Laboratory Medicine, Calgary, Alberta, Canada; Department of Critical Care Medicine, University of Calgary and Calgary Health Region, Calgary, Alberta, Canada; Centre for Anti-microbial Resistance, University of Calgary, Calgary Health Region and Calgary Laboratory Services, Calgary, Alberta, Canada. Electronic address: Kevin.Laupland@CalgaryHealthRegion.ca.
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001398:Aztreonam / Q000627:therapeutic use; D002170:Canada / Q000453:epidemiology; D002391:Catchment Area, Health; D003091:Colistin / Q000627:therapeutic use; D003428:Cross Infection / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification / Q000378:metabolism*; D012189:Retrospective Studies; D015996:Survival Rate; D001618:beta-Lactamases / Q000096:biosynthesis*
D000900:Anti-Bacterial Agents; D001618:beta-Lactamases; D001398:Aztreonam; D003091:Colistin